2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2262

Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2064

Evaluation of Methods to Account for Differential Follow-up When Comparing Clinical Trial Data to Observational Data

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2415

Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2249

Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2466

Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2606

Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2156

Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2339

Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2016

Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2044

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2134

Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2431

Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2330

Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].